Ascletis controlling shareholders commit to voluntary share lock-up

Ascletis Pharma Inc. announced that its controlling shareholders, Dr. Jinzi Jason Wu (founder, chairman, and chief executive) and his spouse, Mrs. Judy Hejingdao Wu (executive director), have voluntarily agreed not to dispose of any company shares they beneficially own, directly or indirectly. This lock-up will remain in effect until the completion of clinical readouts for three key studies.

The clinical readouts include topline data from a U.S. Phase I study of ASC47 with semaglutide (expected by September 2025), topline data from a U.S. Phase IIa 13-week study of ASC30 oral tablet (expected by December 2025), and topline data from a U.S. Phase I single ascending dose study of ASC50 (expected by December 2025). As of September 12, 2025, the total number of shares subject to this voluntary lock-up is 575,952,078, representing approximately 58.03% of the total shares in issue, excluding treasury shares.

The company advises shareholders and potential investors to exercise caution when dealing in the shares. Ascletis also noted there is no guarantee that ASC30, ASC47, and/or ASC50 will be successfully developed, manufactured, and/or commercialized.